RSRahul Shimpi

Rahul Shimpi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rahul Shimpi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factors Influencing Vaccine Receipt During a 2018 Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India

    by Priyanka Borhade, Christopher LeBoa, Niniya Jayaprasad, Kashmira Date, Pradeep Haldar, Pauline Harvey, Rahul Shimpi, Qian An, Chenhua Zhang, Lily Horng, et al.

    : In 2018, the Navi Mumbai Municipal Corporation implemented phase 1 of a public sector typhoid conjugate vaccine campaign in Navi Mumbai, India, targeting all children aged 9 months to 14 years within its administrative boundaries. To assess associations with receipt of vaccine in phase 1, we used generalized estimating equations to calculate estimates of vaccination by child-, household-, and community-level demographics (child education and age; household head education, income, and occupation; community informal settlement percent). Campaign vaccine receipt was most associated with children enrolled in school (odds ratio [OR] = 3.84, 95% CI: 2.18–6.77), the lowest household income tertile when divided into three equal parts (OR = 1.64, 95% CI: 1.43–1.84), and lower community-level socioeconomic status (OR = 1.06, 95% CI: 1.04–1.08 per 10% informal settlement proportion). The campaign was successful in reaching the most underserved populations of its target communities.

  • Open Access

    Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign

    by Kashmira Date, Christopher LeBoa, Seth A. Hoffman, Pradeep Haldar, Pauline Harvey, Qian An, Chenhua Zhang, Vijay N. Yewale, Savita Daruwalla, Dhanya Dharmapalan, et al.

    Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05–0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0–95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.


  • Open Access

    Retrospective Review of Blood Culture-Confirmed Cases of Enteric Fever in Navi Mumbai, India: 2014–2018

    by Niniya Jayaprasad, Priyanka Borhade, Christopher LeBoa, Kashmira Date, Shrikrishna Joshi, Rahul Shimpi, Jason R. Andrews, Stephen P. Luby, Seth A. Hoffman

    India has one of the highest estimated burdens of enteric fever globally. Prior to the implementation of Typbar-TCV typhoid conjugate vaccine (TCV) in a public sector pediatric immunization campaign in Navi Mumbai, India, we conducted a retrospective review of blood culture-confirmed cases of typhoid and paratyphoid fevers to estimate the local burden of disease. This review included all blood cultures processed at a central microbiology laboratory, serving multiple hospitals, in Navi Mumbai (January 2014–May 2018) that tested positive for either Salmonella Typhi or Salmonella Paratyphi A. Of 40,670 blood cultures analyzed, 1,309 (3.2%) were positive for S. Typhi (1,201 [92%]) or S. Paratyphi A (108 [8%]). Culture positivity was highest in the last months of the dry season (April–June). Our findings indicate a substantial burden of enteric fever in Navi Mumbai and support the importance of TCV immunization campaigns and improved water, sanitation, and hygiene.